RSLS - ReShape Lifesciences Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201712/31/201612/31/201512/31/2014
Total Revenue1,287.154786.66290.637-
Cost of Revenue936.386431.476123.684-
Gross Profit350.768355.184166.953-
Operating Expenses
Research Development5,775.0985,169.2868,141.32311,031.619
Selling General and Administrative24,883.54717,981.52519,892.42414,561.656
Non Recurring----
Others----
Total Operating Expenses31,595.03123,582.28728,157.43125,593.275
Operating Income or Loss-30,307.877-22,795.627-27,866.794-25,593.275
Income from Continuing Operations
Total Other Income/Expenses Net-5,824.706-565.2172,368.047-535.445
Earnings Before Interest and Taxes-30,307.877-22,795.627-27,866.794-25,593.275
Interest Expense-3.874-4,104.003-939.182-530.222
Income Before Tax-36,132.583-23,360.844-25,498.747-26,128.72
Income Tax Expense-2,314.611---
Minority Interest----
Net Income From Continuing Ops-33,817.972-23,360.844-25,498.747-26,128.72
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-33,817.972-23,360.844-25,498.747-26,128.72
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-33,817.972-23,360.844-25,498.747-26,128.72